TORONTO, Sept. 07, 2022 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company“), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce, further to the Company’s press release dated December 2, 2021, the amendment and closing of its first tranche of the previously announced non…

Source

Previous articleatai Life Sciences to Participate in September Investor Events
Next articleBright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors